How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease
IPX203 (CREXONT®) is a novel, oral, extended-release (ER) carbidopa-levodopa (CD-LD) formulation, designed to rapidly achieve LD plasma concentrations similar to immediate-release (IR) CD-LD and to maintain LD concentrations for a longer duration than other oral CD-LD products. In the pivotal phase...
Saved in:
| Main Authors: | Robert A. Hauser, Yasar Torres-Yaghi, Stanley Fisher, Ghazal Banisadr |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Clinical Parkinsonism & Related Disorders |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590112525000611 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analytical method for simultaneous quantification of levodopa and carbidopa in the injectable oleogel formulation by HPLC
by: Deepa D. Nakmode, et al.
Published: (2025-02-01) -
Hyponatremia in Parkinson’s Disease: The Impact of Carbidopa-Levodopa Therapy
by: Elizabeth Schumacher, et al.
Published: (2025-06-01) -
Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey
by: Robert A. Hauser, et al.
Published: (2021-01-01) -
Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson’s disease: a disproportionality analysis of the FAERS database
by: Huaide Qiu, et al.
Published: (2025-03-01) -
Symptom improvement in a South Asian patient with Parkinson’s disease treated with immediate- and extended-release carbidopa–levodopa: a case report
by: Gail Reiner, et al.
Published: (2025-07-01)